Valuation: Damora Therapeutics, Inc.

Market Cap 1.75B 1.52B 1.43B 1.3B 2.44B 168B 2.46B 17.12B 6.6B 85.22B 6.58B 6.44B 271B P/E 2026 *
-14.2x
P/E 2027 * -13.8x
Enterprise Value 1.29B 1.12B 1.06B 958M 1.8B 124B 1.81B 12.61B 4.86B 62.78B 4.85B 4.74B 200B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.4%
Yield 2026 *
-
Yield 2027 * -
1 day-12.10%
1 week-13.30%
Current month-10.26%
1 month-18.66%
3 months+26.01%
6 months+1.24%
Current year+9.91%
1 week 24.89
Extreme 24.89
29.29
1 month 24.89
Extreme 24.89
33.56
Current year 16.5
Extreme 16.5001
34.89
1 year 2.72
Extreme 2.724
38.33
3 years 2.01
Extreme 2.01
38.33
5 years 2.01
Extreme 2.01
107.25
10 years 2.01
Extreme 2.01
449.75
Manager TitleAgeSince
Chief Executive Officer 55 29/03/2026
Director of Finance/CFO - 30/04/2026
Chief Tech/Sci/R&D Officer 60 04/01/2026
Director TitleAgeSince
Chairman 40 22/03/2026
Director/Board Member 42 09/11/2025
Director/Board Member 41 09/11/2025
Date Insider Type Main position Quantity % Market Cap. Importance
12/08/26 Free

Director

30,350 0.0493%
06/07/26 Sell

General Counsel

-245 0.0004%
01/05/26 Other

Chief Financial Officer

312,535 0.5077%
Change 5-day change 1-year change 3-year change Capi.($)
-12.10%-13.30%+793.64%+70.68% 1.75B
+0.56%-3.38%-1.83%+8.00% 45.63B
-1.33%-2.41%+337.94%+537.06% 43.96B
+1.71%+4.73%+45.98%+28.23% 43.73B
-1.70%-1.05%+4.67%+73.61% 40.23B
-0.73%-4.72%+8.55%+37.89% 31.86B
-12.53%-14.44% - - 17.4B
+3.04%+4.44%+24.32%+120.43% 16.62B
+1.83%+3.20%+16.49%+32.73% 14.46B
+0.22%-2.38%+80.02%+31.84% 13.04B
Average -2.12%-2.18%+145.53%+104.50% 26.87B
Weighted average by Cap. -0.80%-2.12%+80.87%+128.91%

Financials

2026 *2027 *
Net sales - -
Net income -125M -109M -103M -93.03M -175M -12.02B -176M -1.22B -472M -6.1B -471M -461M -19.39B -150M -130M -123M -111M -209M -14.39B -210M -1.47B -565M -7.3B -564M -552M -23.21B
Net Debt -462M -400M -377M -342M -642M -44.24B -647M -4.51B -1.74B -22.44B -1.73B -1.7B -71.35B -352M -305M -288M -261M -490M -33.72B -493M -3.44B -1.32B -17.1B -1.32B -1.29B -54.38B
Logo Damora Therapeutics, Inc.
Damora Therapeutics, Inc. is a biotechnology company that focuses on hematologic disorders. It is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms (MPN), including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. Its lead asset, DMR-001, is an investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR). It is developing candidates for treatment of essential thrombocythemia (ET), an MPN associated with the overproduction of platelets, and myelofibrosis, an MPN involving the overproliferation of blood cells and deposition of fibrous material in the bone marrow and spleen. DMR-002, an afucosylated antibody designed to enhance antibody-dependent cellular cytotoxicity and amplify natural immune killing of malignant cells. DMR-003, a bi-specific T-cell engager antibody designed to recruit and direct T-cell-mediated killing of malignant cells.
Employees
7
Date Price Change Volume
15/09/26 US$25.20 -11.25% 611,715
14/09/26 US$28.39 +1.03% 372,084
11/09/26 US$28.10 +4.69% 525,410
10/09/26 US$26.84 +2.17% 639,787
09/09/26 US$26.27 -9.94% 500,073
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
28.39USD
Average target price
44.67USD
Spread / Average Target
+57.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DMRA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!